Sarepta Therapeutics Inc (SRPT) Shares Sold by Cambridge Investment Research Advisors Inc.

Cambridge Investment Research Advisors Inc. cut its stake in Sarepta Therapeutics Inc (NASDAQ:SRPT) by 17.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,639 shares of the biotechnology company’s stock after selling 1,011 shares during the period. Cambridge Investment Research Advisors Inc.’s holdings in Sarepta Therapeutics were worth $258,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. BlackRock Inc. lifted its holdings in Sarepta Therapeutics by 0.9% in the fourth quarter. BlackRock Inc. now owns 6,286,343 shares of the biotechnology company’s stock worth $349,773,000 after buying an additional 58,433 shares during the period. Fred Alger Management Inc. increased its stake in shares of Sarepta Therapeutics by 10.5% during the fourth quarter. Fred Alger Management Inc. now owns 1,581,525 shares of the biotechnology company’s stock valued at $87,996,000 after purchasing an additional 149,712 shares in the last quarter. Jennison Associates LLC increased its stake in shares of Sarepta Therapeutics by 0.6% during the fourth quarter. Jennison Associates LLC now owns 1,150,210 shares of the biotechnology company’s stock valued at $63,998,000 after purchasing an additional 6,357 shares in the last quarter. Gilder Gagnon Howe & Co. LLC increased its stake in shares of Sarepta Therapeutics by 63.4% during the fourth quarter. Gilder Gagnon Howe & Co. LLC now owns 872,824 shares of the biotechnology company’s stock valued at $48,564,000 after purchasing an additional 338,737 shares in the last quarter. Finally, Carillon Tower Advisers Inc. bought a new position in shares of Sarepta Therapeutics during the fourth quarter valued at approximately $38,720,000. Institutional investors and hedge funds own 84.98% of the company’s stock.

How to Become a New Pot Stock Millionaire

SRPT has been the subject of a number of analyst reports. Janney Montgomery Scott initiated coverage on shares of Sarepta Therapeutics in a research note on Wednesday, January 3rd. They set a “buy” rating and a $75.00 target price for the company. HC Wainwright set a $75.00 target price on shares of Sarepta Therapeutics and gave the company a “buy” rating in a research note on Wednesday, January 3rd. Oppenheimer reaffirmed a “buy” rating and set a $76.00 target price on shares of Sarepta Therapeutics in a research note on Wednesday, December 27th. BidaskClub raised shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, December 25th. Finally, Nomura raised their target price on shares of Sarepta Therapeutics to $96.00 and gave the company a “buy” rating in a research note on Friday, March 2nd. Four investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $78.87.

Shares of SRPT opened at $79.87 on Wednesday. The company has a market cap of $5,250.25, a P/E ratio of -48.70 and a beta of 1.28. The company has a quick ratio of 12.96, a current ratio of 13.91 and a debt-to-equity ratio of 0.54. Sarepta Therapeutics Inc has a twelve month low of $28.82 and a twelve month high of $84.37.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Thursday, March 1st. The biotechnology company reported ($0.37) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.32) by ($0.05). The firm had revenue of $57.30 million for the quarter, compared to the consensus estimate of $57.33 million. Sarepta Therapeutics had a negative net margin of 32.79% and a negative return on equity of 30.59%. Sarepta Therapeutics’s revenue was up 961.1% on a year-over-year basis. During the same period last year, the business earned ($0.71) EPS. sell-side analysts anticipate that Sarepta Therapeutics Inc will post -1.18 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This article was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/18/sarepta-therapeutics-inc-srpt-shares-sold-by-cambridge-investment-research-advisors-inc.html.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics Inc (NASDAQ:SRPT).

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply